Question · asked by 1 review
N‐acetylcysteine (1200 mg) vs placebo: Patient‐reported pain intensity or pain relief (VAS, NRS or categorical scale)
- Population
- sickle cell disease
- Intervention
- N‐acetylcysteine (1200 mg)
- Comparison
- placebo
- Outcome
- Patient‐reported pain intensity or pain relief (VAS, NRS or categorical scale)
N‐acetylcysteine (1200 mg) showed no clear difference in severity of pain (maximum pain intensity on pain days) compared with placebo (low certainty).
What each review found
Current versions only| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
N‐acetylcysteine (1200 mg) vs placebo Severity of pain (maximum pain intensity on pain days) · sickle cell disease N‐acetylcysteine (1200 mg) showed no clear difference in severity of pain (maximum pain intensity on pain days) compared with placebo (low certainty). Antioxidant supplementation for sickle cell disease (2024) · Cochrane Headline outcomes only | MD 0.17 | 1 study · 96 participants | Low |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Antioxidant supplementation for sickle cell disease 2024 · Cochrane Headline outcomes only | Not reported | Not extracted | Not assessed |
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.